Skip to main content
. Author manuscript; available in PMC: 2014 Jul 6.
Published in final edited form as: Ther Drug Monit. 2007 Dec;29(6):735–742. doi: 10.1097/FTD.0b013e31815d8ace

TABLE 3.

Pharmacokinetic Parameters for MPAG and AcMPAG Normalized to a Dose of 720 mg EC-MPS Twice a Day

Diabetic
(n = 9)		 Nondiabetic
(n = 9)		 P Value
MPAG
 C0 (mg/L) 71.6 (39.1, 177.1) 42.2 (29.0, 131.6) 0.18
 AUC0–12 (mg*h/L) 982.2 (529.2, 1901.4) 669.9 (320.1, 1776.7) 0.38
AcMPAG
 C0 (mg/L) 2.6 (1.4, 5.1) 1.9 (0.7, 5.8) 0.82
 AUC0–12 (mg*h/L) 35.5 (19.6, 76.7) 28.3 (10.6, 82.8) 0.98
Concentration ratio
 MPAG:AcMPAG 25.5 (12.0, 70.3) 23.5 (12.7, 53.2) <0.01

All data expressed as median (minimum, maximum).

MPAG, mycophenolic acid-glucuronide; AcMPAG, acyl-mycophenolic acid-glucuronide; EC-MPS, enteric-coated formulation of the sodium salt derivative of mycophenolic acid; C0, morning trough plasma concentration; AUC0–12, area under the concentration–time curve from 0 to 12 hours.